UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for su ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Results Conference Call August 15, 2023 8:30 AM ET Company Participants John Menditto - VP, IR and Corporate Communications Dr. David Mazzo - President and Chief Executive Officer Dr. Kristen Buck - EVP, Research and Development and Chief Medical Officer James Nisco - VP, Finance and Treasury Conference Call Participants Steve Brozak - WBB Securities Pete Enderlin - MAZ Partners Kemp Dolliver - Brookline Capital Markets Operator Welcome to the Lisata Therapeut ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants John Menditto - VP, IR and Corporate Communications David Mazzo - CEO James Nisco - VP, Finance and Treasury Kristen Buck - EVP, Research and Development and Chief Medical Officer Conference Call Participants Steve Brozak - WBB Securities Kemp Dolliver - Brookline Capital Markets Pete Enderlin - MAZ Partner Joe Pantginis - H.C. Wainwright Operator Welcome to the Lisata Therapeutics First Quar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delawar ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) D ...

2nd line Esophageal SCC (after failure on first line IO) Sponsor/Partner Qilu Pharmaceutical (funds all development in China) Phase 2b, double-blind, placebo-controlled, randomized study evaluating LSTA1 + SoC (Qilu-produced nab-paclitaxel and gemcitabine) vs. placebo + SoC Objective response rate, progression free survival, overall survival Safety 47 • Sponsor/Partner: Qilu Pharmaceutical (funds all development in China) Gemcitabine + Qilu produced nab-paclitaxel + LSTA1 3.2 mg/kg Disease Progression MORPH ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants John Menditto - VP, IR and Corporate Communications Dave Mazzo - CEO David Slack - President and Chief Business Officer James Nisco - VP, Finance and Treasury Kristen Buck - EVP, Research and Development and Chief Medical Officer Conference Call Participants Peter Enderlin - MAZ Partners Shubhendu Roy - Brooklyn Capital Markets Operator Welcome to the Lisata Therapeutics Third Quarter 2 ...

LISTHER ATAPEUTICS A Targeted Therapy Delivered David J. Mazzo, Ph.D. Chief Executive Officer LD Micro Main Event XV| October 2022 Nasdaq: LSTA www.lisata.com Copyright ©2022 Lisata Therapeutics, Inc. All rights reserved. Forward-looking Statements This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, i ...

Caladrius Biosciences, Inc. (CLBS) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO Kristen Buck - EVP, Research and Development & CMO James Nisco - VP, Finance & Treasury Conference Call Participants Kumar Raja - Brookline Capital Pete Enderlin - MAZ Partners Operator Welcome to the Caladrius Biosciences' Second Quarter 2022 Financial Results and Business Update Conference Call. Currently all partic ...